Category Archives: Mesenchymal Stem Cells

LEUVEN, BELGIUM--(Marketwire -07/10/12)- TiGenix (EURONEXT:TIG) announced today the enrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn's disease patients at Hospital Clnic, Barcelona, Spain. Cx601 is an adipose derived allogeneic stem cell therapy. ADMIRE-CD is a multicenter, randomized, double-blind, placebo-controlled Phase III trial of Cx601 in approximately 200 Crohn's disease patients suffering from complex perianal fistulas. The main objectives of the study are to demonstrate safety and superior efficacy over placebo in perianal fistulas in Crohn's disease patients after failure with their previous treatment, in most cases biologicals, and to confirm the strong safety and efficacy results from the Phase II trial completed in 2011. To date, the company has already received approvals from Ethical Committees or Regulatory Agencies in 7 out of 8 countries, which should allow the company to accelerate patient enrolment in the study. Dr. Jose Luis Bravo, VP Global Medical Affairs & Clinical Development of TiGenix, said: "We are delighted to enrol the first patient in the ADMIRE-CD trial. Hospital Clnic has pioneered the use of stem cell therapies to treat Crohn's disease, and we believe that Cx601 may prove to be a … Continue reading →

REHOVOT, Israel and PARIS, July 9, 2012 /PRNewswire/ -- BioView Ltd. (BIOV.TA) and ScreenCell, a privately-held company, today jointly announced the signing of a commercial collaboration agreement for Bioview's Automated Cell Imaging Systems for imaging of CTC's isolated with ScreenCell's Cyto Kit . Dr. Alan Schwebel, President and CEO of BioView, views this agreement as a unique combination of two innovative technologies, one designed by ScreenCell to isolate rare cells of potentially significant prognostic and predictive value in cancer, and another, BioView's scanning platform, which provides automated imaging and analysis solutions for rare cell and circulating tumor cell detection. "BioView's unique automated imaging and analysis solutions for the detection and of rare cells greatly enhance research and clinical laboratory productivity and assay development process. We are proud to be ScreenCell's global partner and look forward to expanding our relationship." Bioview's Imaging Systems are designed to accommodate both the need for CTC enumeration and retrieval of cellular and marker characteristics of captured cells. Utilizing field-proven algorithms developed and perfected in collaboration with leading cancer research centers worldwide, BioView's scanning platform is the ideal solution for both clinical and research laboratories wishing to enhance their productivity and assay development processes. ScreenCell offers … Continue reading →

Durham, NC (PRWEB) July 09, 2012 A new study released today in STEM CELLS Translational Medicine shows the potential of a new approach in preparing stem cells that provide relief to people suffering from a common, yet painful diabetes complication. About 70 percent of diabetics have neuropathy, or nerve damage, resulting from the disease, according to the National Institutes of Health. The most common type is peripheral neuropathy (DPN), which causes pain or loss of feeling in the toes, feet, legs, hands and arms. Up to a quarter of DPN sufferers endure an extremely painful version (pDPN) in which even a tiny amount of external pressure can be excruciating. While there are many contributors to DPN, inflammation is considered a major culprit. Treatments are generally restricted to controlling the diabetes itself and to alleviating pain with topical ointments such as capsaicin cream or with oral medications including antidepressants and anticonvulsants. However, none of these therapies directly targets the inflammation, most have negative side effects and less than 30 percent of patients experience adequate pain relief. Clearly, new therapies are needed, said Dr. Ruth Waterman of the Ochsner Clinic Foundation in New Orleans. Dr. Waterman collaborated with Dr. Aline Betancourt from … Continue reading →

MANILA, Philippines Stem cell therapy, aside from being a potential cure for a wide range of illnesses, can also make a patient look and feel younger, a stem cell therapist said. Dr. Ricardo Quiones, a cosmetic surgeon and dermatologist, has trained to conduct stem cell therapy, which he describes as the future of medicine. Quiones said stem cell therapy has become popular for its ability to regenerate and heal properties of adult stem cells. As we grow old, our stem cells dramatically decline. When we were children, we had 80 million stem cells. As we reach the age of 40, our stem cells decline to 35 million, he told Mornings@ANC on Friday. Quiones explained that the procedure is similar to turning back the clock because it can increase a persons stem cells to 100 million. Ive done two patients from Zamboanga City. I called them up after the procedure and they told me they look younger. They have the stamina, the vigor and they have felt an increase in short-term memory, powers of attention and concentration, he said. Quiones also said the procedure has the potential to cure diabetes, heart damage, brain damage such as Parkinsons and Alzheimers, osteoarthritis, stroke, … Continue reading →

Patients in a clinical trial who received Osiris Therapeutics stem cell treatment within a week after experiencing their first heart attack showed "significantly less" damage and arrhythmia than those who received a placebo. The interim one-year results are from a phase 2 trial of Prochymal involving 220 heart attack patients, ages 21 to 85. "This study is the largest of its kind and provides key insights into the mechanism of action of mesenchymal stem cells in the setting of acute myocardial infarction," Lode Debrabandere, senior vice president of therapeutics at the Columbia company, said in a statement. "These important mechanistic observations are consistent with data obtained from our preclinical models and from the first placebo-controlled human trial with Prochymal published in the Journal of the American College of Cardiology. Given the quality of the data and highly encouraging results observed thus far, we are extending the trial's duration to capture a better understanding of the long-term clinical benefits ..." Furthermore, the trial showed that the treatment is safe, with no toxicities seen in patients who received it. So far, there have been five deaths in the trial: two in the Prochymal group and three in the placebo group. "For interventional … Continue reading →

SHENZHEN, China, July 3, 2012 /PRNewswire-Asia/-- A study conducted by Beike Biotechnology Company (http://www.beikebiotech.com) in conjunction with physicians and researchers at two Chinese hospitals, documents the effectiveness of cord blood-derived stem cells in treating primary biliary cirrhosis (PBC). The study, which was published in the April 2012 issue of the Stem Cell Discovery, was the first of its kind. Researchers noted that additional clinical trials would be required before stem cells can become an accepted therapy for liver cirrhosis. Prof. Jin-hui Yang, Director of the Department of Hepatology in the 2nd Affiliated Hospital of Kunming Medical College stated, "Given the severity of liver cirrhosis and its related conditions, and the limited number of options available to treat those who suffer from it, this finding represents an important, potentially significant breakthrough." PBC is a chronic, progressive liver disease that leads eventually to fibrosis and cirrhosis of the liver. It affects 1 in 1,000 women over the age of 40.Approximately one-third of those who suffer from PBC and its related conditions do not respond well to Ursodeoxycholic acid (UDCA) treatment, which is the only currently FDA-approved standard medical treatment for the condition. Many of those patients ultimately require liver transplantation. Beike Chairman, … Continue reading →

Tuesday, July 03 16:25:12 Ireland has the capacity to be an international centre for commercialisation in the field of regenerative medicine, delegates at an international stem cell conference in NUI Galway heard today. Reflecting this potential, new Irish company Orbsen Therapeutics is developing proprietary technologies designed to isolate stem cells. The NUI Galway spin-out is targeting the rapidly maturing and expanding regenerative medicine market, which is expected to grow to $118 billion next year. Frank Barry is Professor of Cellular Therapy at NUI Galway, Director of Orbsen Therapeutics, and organiser of the Mesenchymal Stem Cell Conference, which opened yesterday. Mesenchymal stem cells (MSCs) are a type of adult stem cell, and this event brings together the world's leading scientists in the field to discuss their latest ideas and findings. This is the first major stem cell conference to take place in Ireland, and is looking at all aspects of adult stem cells, from basic biology to manufacturing to clinical trials and therapeutics. Stem cells hold great promise as an alternative to drugs and surgical procedures for treating a wide range of medical conditions including heart disease, arterial disease of the limbs, diabetes complications, arthritis and other inflammatory conditions. The treatment … Continue reading →

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the second patient in its Phase 1/2 clinical trial for Stargardts macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, June 29 at Moorfields Eye Hospital in London, the same site as the first patient treatment in January, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The procedure was successfully performed without any complications. ACT and Moorfields Eye Hospital recently received clearance from the Data and Safety Monitoring Board (DSMB) to treat the final two patients in the first cohort of this clinical trial. We are very pleased to continue our forward momentum with both our U.S. trials and our European trial, commented Gary Rabin, chairman and CEO. It was less than a month ago that we received DSMB approval to treat the second and third patients in our E.U. trial, and it is very gratifying to have already completed dosing of the second. It is a pleasure to be … Continue reading →

02-07-2012 09:43 State of the Nation is a nightly newscast anchored by award-winning broadcast journalist, Jessica Soho. It airs Mondays to Fridays at 9:00 PM (PHL Time) on GMA News TV Channel 11. For more videos from State of the Nation, visit fthenation. Follow this link: SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan - Video … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), announced today interim one-year results from its groundbreaking clinical trial evaluating Prochymal (remestemcel-L) for the treatment of patients experiencing first-time acute myocardial infarction. The trial is the largest study of allogeneic or "off-the-shelf" stem cells ever conducted in heart attack patients. A total of 220 patients were given a single infusion of either Prochymal or placebo through a standard intravenous line within seven days of an acute heart attack. Cardiac MRI assessments were conducted for six months following infarct to evaluate cardiac remodeling. Patients receiving Prochymal had significantly less cardiac hypertrophy, as measured by cardiac MRI, compared to patients receiving placebo (p … Continue reading →